SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001493152-22-021341
Filing Date
2022-08-04
Accepted
2022-08-04 16:30:50
Documents
3
Group Members
ATG CAPITAL MANAGEMENT, LLC

Document Format Files

Seq Description Document Type Size
1 form-sc13d.htm SC 13D 104354
2 ex-1.htm EX-1 11106
3 ex-2.htm EX-2 48097
  Complete submission text file 0001493152-22-021341.txt   165270
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-89959 | Film No.: 221137115
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ATG CAPITAL MANAGEMENT, LLC 805 N. MILWAUKEE AVE., STE. 301 CHICAGO IL 60642
Business Address C/O ATG CAPITAL MANAGEMENT, LLC 805 N. MILWAUKEE AVE., STE. 301 CHICAGO IL 60642 (786) 519-0995
ATG Fund II LLC (Filed by) CIK: 0001940093 (see all company filings)

IRS No.: 882296572 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D